Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)
Terminated
Merck Sharp & Dohme Corp.
Phase 2/Phase 3
Study P05063 is a 3-year long-term follow-up (LTFU) study in participants previously treated
with boceprevir (BOC) or narlaprevir (NAR) in a Phase 1, 2, or 3 clinical study. Participants
will be followed for up to 3.5 years after the end of their participation in the treatment
protocol to document maintenance of the antiviral response (for sustained responders) and to
characterize the long-term safety after use of this therapeutic regimen. LTFU procedures
include collection of plasma samples for measuring Hepatitis C Virus ribonucleic acid
(HCV-RNA) by polymerase chain reaction (PCR) and HCV sequence analysis. No drug therapy will
be administered as part of this study.
Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695)
Completed
Merck Sharp & Dohme Corp.
Phase 1
Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCH 900518
in Naive or Treatment-Experienced Subjects Infected With Hepatitis C Virus Genotype 1
(Protocol No. P04695)
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b
Completed
Almedis
Phase 2
The purpose of this study is to confirm that combination of Narlaprevir, Ritonavir and
Daclatasvir is safe and highly effective regimen in treatment-naїve patients with chronic
hepatitis C (HCV) genotype 1b infection.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
